Jw Asset Management Lowers stake in Concordia Healthcare Corp (CXRX)

Concordia Healthcare Corp (CXRX) : Jw Asset Management reduced its stake in Concordia Healthcare Corp by 54.11% during the most recent quarter end. The investment management company now holds a total of 245,400 shares of Concordia Healthcare Corp which is valued at $6.5 Million after selling 289,400 shares in Concordia Healthcare Corp , the firm said in a disclosure report filed with the SEC on May 12, 2016.Concordia Healthcare Corp makes up approximately 4.16% of Jw Asset Management’s portfolio.

Other Hedge Funds, Including , Greystone Managed Investments boosted its stake in CXRX in the latest quarter, The investment management firm added 685,554 additional shares and now holds a total of 2,014,863 shares of Concordia Healthcare Corp which is valued at $53 Million. Concordia Healthcare Corp makes up approx 1.99% of Greystone Managed Investments’s portfolio.Shell Asset Management Co reduced its stake in CXRX by selling 108 shares or 2.74% in the most recent quarter. The Hedge Fund company now holds 3,833 shares of CXRX which is valued at $100,808.Nebula Capital Management Lp boosted its stake in CXRX in the latest quarter, The investment management firm added 38,400 additional shares and now holds a total of 197,000 shares of Concordia Healthcare Corp which is valued at $4.8 Million. Concordia Healthcare Corp makes up approx 3.52% of Nebula Capital Management Lp’s portfolio. Checchi Capital Advisers added CXRX to its portfolio by purchasing 117 company shares during the most recent quarter which is valued at $2,872.Great West Life Assurance Co Can reduced its stake in CXRX by selling 718,259 shares or 65.02% in the most recent quarter. The Hedge Fund company now holds 386,400 shares of CXRX which is valued at $11.3 Million. Concordia Healthcare Corp makes up approx 0.04% of Great West Life Assurance Co Can’s portfolio.

On the company’s financial health, Concordia Healthcare Corp reported $1.35 EPS for the quarter, missing the analyst consensus estimate by $ -0.05 based on the information available during the earnings call on May 13, 2016. Analyst had a consensus of $1.40. The company had revenue of $228.50 million for the quarter, compared to analysts expectations of $228.07 million. The company’s revenue was up 570.1% compared to the same quarter last year.

Concordia Healthcare Corp. is a Canada-based diverse healthcare company. The Company is focused on legacy pharmaceutical products and orphan drugs. The Company operates through three segments which includes Legacy Pharmaceutical Division Concordia Pharmaceuticals Inc. which consists of 23 products including Nilandron for the treatment of metastatic prostate cancer; Dibenzyline for the treatment of pheochromocytoma; Lanoxin for the treatment of mild-to-moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; Donnatal for the treatment of irritable bowel syndrome and Zonegran (zonisamide) for treatment of partial seizures in adults with epilepsy. Its Specialty Healthcare Distribution (SHD) Division Complete Medical Homecare is engaged in the distribution of medical supplies focused on diabetes and related conditions. Its Orphan Drugs Division Concordia Laboratories Inc. is engaged in the manufacture of PHOTOFRIN.

Leave a Reply

Concordia Healthcare Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Concordia Healthcare Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.